| 1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+ IPI) or NIVO alone C Robert, GV Long, J Larkin, JD Wolchok, JC Hassel, D Schadendorf, ... Annals of Oncology 31, S734-S735, 2020 | 9 | 2020 |
| 114Inm oxine-labelled lymphocytes—therapeutic applications D Hamilton, RA Cowan, M Drayson, H Sharma, PEC Cummins, PM Nuttall, ... Nuclear Medicine Communications 9 (10), 797-802, 1988 | 3 | 1988 |
| 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced … J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... European Journal of Cancer 51, S664-S665, 2015 | 51 | 2015 |
| 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) P Sharma, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... European Journal of Cancer 3 (51), S708, 2015 | 10 | 2015 |
| 40 Adjuvant taxane chemotherapy is associated with a significant risk of febrile neutropenia A Caley, G Bertelli, M Rolles, J Wagstaff, M Moe, D Pudney EJC Supplements 3 (8), 70, 2010 | 4 | 2010 |
| 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+ IPI) combination therapy in advanced melanoma JMG Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, C Lao, ... Annals of Oncology 30, v904-v905, 2019 | 25 | 2019 |
| 7106 Predictive and prognostic factors in a phase III study of pazopanib in patients with advanced renal cell carcinoma (RCC) C Sternberg, I Davis, J Wagstaff, R Hawkins, M Chen, J Ding EJC Supplements 2 (7), 424, 2009 | 1 | 2009 |
| 7162 POSTER A Pan-European Study of Treatment (trx) Patterns and Toxicity of Angiogenesis Inhibitors in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) A Levy, C Porta, R Hawkins, J Bellmunt, J Wagstaff, P Donnellan, ... European Journal of Cancer, S524, 2011 | | 2011 |
| 723 TREATMENT (TRX) PATTERNS AND TOXICITY OF ANGIOGENESIS INHIBITORS IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN UNITED KINGDOM (UK) R Hawkins, J Wagstaff, P Nathan, SP Sarda, F Vekeman, C Korves, ... European Urology Supplements 2 (10), 231, 2011 | | 2011 |
| A COMPARISON OF 3 LOADING REGIMENS OF SURAMIN IN CANCER-PATIENTS REN VANRIJSWIJK, J WAGSTAFF, AC VANLOENEN, HM PINEDO EUROPEAN JOURNAL OF CANCER 26 (2), 185-185, 1990 | | 1990 |
| A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour CHN Veenhof, R de Wit, BG Taal, LY Dirix, J Wagstaff, A Hensen, ... European Journal of Cancer 28 (1), 75-78, 1992 | 40 | 1992 |
| A method for following human lymphocyte traffic using indium-111 oxine labelling. J Wagstaff, C Gibson, N Thatcher, WL Ford, H Sharma, W Benson, ... Clinical and experimental immunology 43 (3), 435, 1981 | 91 | 1981 |
| A method for studying the dynamics of the primary migration of human lymphocytes using Indium-iii oxine cell labelling J Wagstaff, C Gibson, N Thatcher, D Crowther In Vivo Immunology: Histophysiology of the Lymphoid System, 153-160, 1982 | 5 | 1982 |
| A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma WP Steward, IDH Todd, M Harris, JM Jones, G Blackledge, J Wagstaff, ... European Journal of Cancer and Clinical Oncology 20 (7), 881-889, 1984 | 39 | 1984 |
| A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion D Smith, J Wagstaff, N Thatcher, H Scarffe Cancer chemotherapy and pharmacology 20, 327-331, 1987 | 17 | 1987 |
| A phase I study of recombinant interferon gamma administered by sc injection three times per week in patients with solid tumours J Wagstaff, D Smith, P Nelmes, P Loynds, D Crowther Cancer Immunology, Immunotherapy 25, 54-58, 1987 | 27 | 1987 |
| A phase I study of sequential human recombinant interferon-gamma and recombinant interleukin-2 in patients with metastatic solid tumors JW Baars, J Wagstaff, E Boven, JB Vermorken, CJ van Groeningen, ... Journal of the National Cancer Institute 83, 1408-1410, 1991 | | 1991 |
| A phase I toxicity study of human rDNA interferon in patients with solid tumours J Wagstaff, G Chadwick, A Howell, N Thatcher, JH Scarffe, D Crowther Cancer chemotherapy and pharmacology 13, 100-105, 1984 | 16 | 1984 |
| A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma A Baars, AME Claessen, J Wagstaff, G Giaccone, RJ Scheper, S Meijer, ... British Journal of Cancer 86 (8), 1230-1234, 2002 | 79 | 2002 |
| A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma J Wagstaff, P Loynds, D Crowther Cancer chemotherapy and pharmacology 18, 54-58, 1986 | 52 | 1986 |
Robert HawkinsCancer Studies, University of Manchester在 ics.manchester.ac.uk 的电子邮件经过验证
